GTHX Shares Outstanding History
Below is a table of the GTHX shares outstanding history going back to 5/17/2017:

Date GTHX Shares Outstanding

Also see: GTHX Market Cap History
GTHX Historical Shares Outstanding:
+9.12% CAGR
GTHX Historical Shares Outstanding: +9.12% CAGR

Mouse over chart for data details
5/17/2017 ...10/28/2022
G1 Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Co.'s primary compound trilaciclib is a therapy designed to help protect against chemotherapy-induced myelosuppression. Trilaciclib helps protect hematopoietic stem and progenitor cells in the bone marrow by transiently inhibiting CDK4/6 leading to a temporary arrest of susceptible host cells during chemotherapy in patients. Rintodestrant is an oral selective estrogen receptor degrader for the treatment of ER+ breast cancer. We show 24 historical shares outstanding datapoints in our coverage of GTHX's shares outstanding history.

Understanding the changing numbers of GTHX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like GTHX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching GTHX by allowing them to research GTHX shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree GTHX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
G1 Therapeutics (GTHX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

GTS Shares Outstanding History
GTXI Shares Outstanding History
HAE Shares Outstanding History
HAIR Shares Outstanding History
HALO Shares Outstanding History
HARP Shares Outstanding History
HBIO Shares Outstanding History
HCA Shares Outstanding History
HCWB Shares Outstanding History
HEPA Shares Outstanding History
More Healthcare companies »


GTHX Shares Outstanding History | | Copyright © 2017 - 2022, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.